Semaglutide vs. Tirzepatide: What These Drugs Actually Do to Your Body Composition

Two of the most powerful weight loss medications ever developed share a troubling side effect that almost nobody talks about in the mainstream conversation: they eat your muscle. A 2025 network meta-analysis published in Metabolism: Clinical and Experimental analyzed 22 randomized controlled trials covering 2,258 participants and found that roughly 25% of the total weight lost on GLP-1 receptor agonists came from lean mass — not fat. For a man losing 40 pounds on semaglutide or tirzepatide, that means approximately 10 pounds of that loss could be muscle. That is not a rounding error. That is a body composition crisis hiding inside a weight loss success story.

This does not mean these medications are bad or that men should avoid them. The data on fat loss, visceral adipose tissue reduction, cardiovascular protection, and metabolic improvement is genuinely impressive. But understanding what semaglutide and tirzepatide actually do — and do not do — to your physique gives you the information you need to use them intelligently, or to understand the same physiological principles whether you are on a GLP-1, running a calorie deficit the old-fashioned way, or just trying to recomp at the gym.

How These Drugs Work and Why Body Composition Gets Complicated

Semaglutide is a GLP-1 receptor agonist, meaning it mimics the gut hormone glucagon-like peptide-1 to suppress appetite, slow gastric emptying, and improve insulin secretion. At the 2.4 mg weekly subcutaneous dose approved for obesity, it produces mean weight loss of 15–17% of body weight. Research published in the International Journal of Obesity notes its established cardioprotective benefits alongside that weight loss, which helped cement its clinical standing.

Tirzepatide goes further by acting on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously — making it a dual agonist with a distinct pharmacological profile. Phase 3 obesity trials showed it could produce up to 22.5% mean weight loss, a figure that approaches what bariatric surgery achieves. A 2024 systematic review in Diseases confirmed that tirzepatide produces superior reductions in total fat mass, visceral adipose tissue, and waist circumference compared to other anti-obesity medications including semaglutide and dulaglutide over equivalent treatment durations. The visceral fat data is particularly meaningful — visceral adipose tissue is the metabolically active, organ-surrounding fat most strongly linked to insulin resistance, cardiovascular disease, and systemic inflammation.

So both drugs are highly effective at driving fat loss, especially the dangerous kind. The complexity emerges when you look at what happens to lean tissue during that same period. The 2025 meta-analysis found that while GLP-1 receptor agonists significantly reduced fat mass by a mean of 2.95 kg, they also reduced lean mass by a mean of 0.86 kg. Tirzepatide at 15 mg weekly and semaglutide at 2.4 mg weekly were identified as the most effective agents for weight and fat mass reduction — but simultaneously among the least effective at preserving lean mass. Interestingly, liraglutide at lower doses was the only GLP-1 agent to achieve significant weight reduction without a statistically significant lean mass loss, likely because the overall weight loss was more modest. This is a classic dose-response tradeoff: more aggressive fat loss tends to come with greater collateral loss of muscle when the hormonal and caloric environment is not optimized.

The mechanism driving fat loss with tirzepatide adds another layer of nuance. A 2023 study in Diabetes Care directly comparing tirzepatide 15 mg, semaglutide 1 mg, and placebo found that while both active drugs significantly reduced appetite versus placebo, appetite scores and energy intake reductions did not significantly differ between tirzepatide and semaglutide. Yet tirzepatide still produced greater fat mass reduction. This suggests tirzepatide’s advantage may lie in mechanisms beyond simple appetite suppression — possibly improved substrate utilization, altered energy expenditure, or GIP receptor-mediated effects on adipose tissue metabolism. The exact pathway is still being investigated, but it reinforces that these are not simple starvation drugs. They are doing something more nuanced to metabolism itself.

The Muscle Problem — and What to Do About It

Losing 10% of your lean mass in the course of a weight loss program is not trivial. A 2024 narrative review in Diabetes Care put this in stark terms: the lean mass loss associated with incretin-based therapies — roughly 6 kg on average — is comparable to a decade or more of normal aging-related muscle loss. That comparison matters because sarcopenia, the progressive loss of muscle mass and function, is strongly linked to increased mortality, metabolic dysfunction, falls, fractures, and reduced quality of life. You do not have to be elderly for this to matter. A 45-year-old man who loses significant muscle during a 12-month weight loss journey has accelerated his physiological aging trajectory, even if he looks leaner in the mirror.

The same review makes the solution clear: supervised resistance exercise training lasting more than 10 weeks can produce approximately 3 kg of lean mass gain and roughly 25% increases in strength. That is not a small effect. Stacked against the 6 kg of lean mass that incretin therapy can strip away, a well-designed resistance training program essentially cuts that muscle loss in half — or potentially eliminates it entirely when protein intake is optimized alongside the training stimulus. The authors explicitly recommend resistance exercise as a tailored adjunct to incretin therapy, framing it not as optional lifestyle advice but as a clinical countermeasure to a known pharmacological side effect.

This principle holds regardless of whether you are on a GLP-1 medication. Any significant caloric deficit — whether driven by a drug that suppresses appetite or by disciplined food choices — creates the conditions for lean mass loss if resistance training and adequate protein are not in place. The drug just accelerates the timeline and amplifies the stakes. For men on semaglutide or tirzepatide, the urgency is higher because the weight loss is faster and more dramatic. But the solution is the same one that has always worked: lift heavy, eat enough protein, and give your body a reason to hold onto muscle while it sheds fat.

Practically speaking, this means prioritizing compound movements — squats, deadlifts, rows, presses — at least three times per week, with progressive overload as the guiding principle. Protein intake should be anchored at a minimum of 1.6 grams per kilogram of body weight, with research supporting intakes up to 2.2 g/kg for men in a deficit who are training seriously. If you are on a GLP-1 and your appetite is suppressed, hitting protein targets requires intention — it will not happen by default when you are eating 1,400 calories a day. Tracking protein specifically, not just total calories, becomes critical in this context.

The pipeline for next-generation obesity medications — including retatrutide (a triple GLP-1/GIP/glucagon agonist) and bimagrumab, an agent that specifically targets muscle and fat composition rather than weight alone — suggests that the field is actively working to solve this lean mass problem. Early data on these emerging compounds indicates that improving body composition outcomes, not just the number on the scale, is becoming a central goal of obesity pharmacotherapy. Until those agents arrive, however, the most evidence-backed intervention for preserving muscle during aggressive weight loss remains resistance training.

What This Means For You

Whether you are using semaglutide or tirzepatide, running a traditional calorie deficit, or somewhere in between, the body composition data from these drug trials tells a story that applies to every man trying to get lean: weight loss and fat loss are not the same thing, and the scale cannot tell the difference between muscle and adipose tissue. Tirzepatide produces remarkable fat loss, particularly visceral fat, and its metabolic benefits are real and significant. But without a deliberate strategy to preserve muscle — through resistance training, adequate protein, and intelligent programming — a portion of that weight coming off will be tissue you cannot afford to lose. The medication handles the fat. The training handles the muscle. You need both sides of that equation working together.